Aldatu Secures $1.5M NIH Grant to Commercialize HIV Drug-Resistance Test | GenomeWeb

NEW YORK (GenomeWeb) – Startup Aldatu Biosciences this month received a two-year, $1.5 million grant from the National Institutes of Health to finalize development of a novel qPCR-based platform for HIV drug-resistance testing in sub-Saharan Africa.

With the support of the direct-to-Phase II Small Business Innovation Research grant, the Cambridge, Massachusetts-based company aims to develop a thermostablized version of the genotyping test, which it will initially launch in Botswana and Tanzania in partnership with research institutes and public health agencies in those nations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Sponsored by

This webinar will discuss a partnership model for noninvasive prenatal testing that enabled LifeLabs Genetics, a genetic testing lab based in Toronto, Ontario, to implement NIPT in house.